Avalyn Pharma
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
We do not have this company's yearly figures yet, so its profit, growth, price and debt cannot be judged here.
Money in, money out
What Avalyn Pharma sold, what it kept, and what it did with the cash.
Sales went from $0 in 2024 to $0 in 2025, with -$85.2 million of profit last year.
Avalyn Pharma vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Avalyn Pharma | No profit yet | ||
 Atai Beckley N.V | No profit yet | ||
 Cullinan Therapeutics | No profit yet | ||
 High Tide | No profit yet | ||
 Satellos Bioscience | No profit yet |
AI analysis
An AI analyst reads Avalyn Pharma's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2024 | 2025 |
|---|---|---|
| 0 | 0 | |
| – | – | |
| -57 | -91 | |
| -57 | -91 | |
| -50 | -85 | |
| -1.19 | – | |
| – | – | |
| – | – | |
| – | – |
Balance sheet
| In millions of USD | 2024 | 2025 |
|---|---|---|
| Total assets | 125 | 149 |
| Cash | 24 | 52 |
| Total debt | 0 | 2 |
| Total liabilities | 299 | 388 |
| -175 | -239 | |
| 42 | – | |
| – | – | |
| 28.5% | 35.7% |
Cash flow
| In millions of USD | 2024 | 2025 |
|---|---|---|
| -48 | -81 | |
| 0 | 0 | |
| -48 | -82 | |
| Dividends paid | – | – |
| – | – | |
| 2 | 3 |
Valuation
- –
- –
- –
- –
- –
- –
- –
- –
- –
- –
Profitability
- –
- –
- –
- –
- –
- –
- –
- –
- –
- –
Growth
- –
- –
- –
- –
- –
Financial health
- –
- –
- –
- –
- –
- –
- –
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
Not enough data
Questions about Avalyn Pharma
Is Avalyn Pharma a good stock to buy?
We do not have this company's yearly figures yet, so its profit, growth, price and debt cannot be judged here. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Avalyn Pharma AI analysis
What does Avalyn Pharma do?
Avalyn Pharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). It is in Medical - Pharmaceuticals.
Does Avalyn Pharma pay a dividend?
No. Avalyn Pharma does not pay a dividend at the moment.
Is Avalyn Pharma stock halal?
Yes. Avalyn Pharma passes our halal screen: its business is permitted and its debt is 0.1% of its market value, under the 30% limit. How we check
Who are Avalyn Pharma's competitors?
The largest listed companies in the same industry are Atai Beckley N.V, Cullinan Therapeutics, High Tide and Satellos Bioscience. The peers table on this page compares their profit, growth and price with Avalyn Pharma's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.